Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: Findit who wrote (98587)	11/14/2003 8:11:17 AM
From: manny t	Read Replies (1) \| Respond to of 208838

CRXL, Dow Jones Business News Crucell Presents "Encouraging" Malaria Vaccine Results Friday November 14, 5:27 am ET Edited Press Release AMSTERDAM -(Dow Jones)- Dutch biotechnology company Crucell N.V. Friday presented encouraging study results on the efficacy of an experimental malaria vaccine at the Viral Vectors & Vaccines conference held in Las Vegas. ADVERTISEMENT The study is part of a close collaboration between Crucell and the Department of Medical and Molecular Parasitology at New York University to provide proof of principle that a vaccine based on Crucell's AdVac technology is able to confer protection against malaria. The studies presented at the conference show that a single shot of an experimental vaccine (a recombinant Adenovirus 35 vector expressing circumsporozoite protein ) protects mice against infection with the mouse malaria parasite Plasmodium yoelii. Crucell has shown in earlier studies, conducted in collaboration with Harvard Medical School, that its rAd35-based vaccines are not hampered by pre-existing adenovirus 5 (Ad5) immunity. In contrast to Ad35, antibodies to Ad5 are widespread among humans of all ages and are known to lower the immune response and thereby impair rAd5-based vaccine efficacy. Despite this, the most commonly used recombinant vaccine systems are currently based on Ad5.